117 related articles for article (PubMed ID: 12110408)
1. Intervention thresholds for osteoporosis.
Kanis JA; Johnell O; Oden A; De Laet C; Oglesby A; Jönsson B
Bone; 2002 Jul; 31(1):26-31. PubMed ID: 12110408
[TBL] [Abstract][Full Text] [Related]
2. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden.
Kanis JA; Johnell O; Oden A; Borgstrom F; Johansson H; De Laet C; Jönsson B
Osteoporos Int; 2005 Jan; 16(1):6-14. PubMed ID: 15103452
[TBL] [Abstract][Full Text] [Related]
3. Intervention thresholds for osteoporosis in the UK.
Kanis JA; Borgstrom F; Zethraeus N; Johnell O; Oden A; Jönsson B
Bone; 2005 Jan; 36(1):22-32. PubMed ID: 15663999
[TBL] [Abstract][Full Text] [Related]
4. Cost-effective osteoporosis treatment thresholds in Greece.
Makras P; Athanasakis K; Boubouchairopoulou N; Rizou S; Anastasilakis AD; Kyriopoulos J; Lyritis GP
Osteoporos Int; 2015 Jul; 26(7):1949-57. PubMed ID: 25740208
[TBL] [Abstract][Full Text] [Related]
5. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
[TBL] [Abstract][Full Text] [Related]
7. Effect and offset of effect of treatments for hip fracture on health outcomes.
Jonsson B; Kanis J; Dawson A; Oden A; Johnell O
Osteoporos Int; 1999; 10(3):193-9. PubMed ID: 10525710
[TBL] [Abstract][Full Text] [Related]
8. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis.
Borgström F; Johnell O; Kanis JA; Jönsson B; Rehnberg C
Osteoporos Int; 2006 Oct; 17(10):1459-71. PubMed ID: 16847588
[TBL] [Abstract][Full Text] [Related]
9. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
Ni W; Jiang Y
Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of preventing hip fracture in the general female population.
Kanis JA; Dawson A; Oden A; Johnell O; de Laet C; Jonsson B
Osteoporos Int; 2001; 12(5):356-61. PubMed ID: 11444082
[TBL] [Abstract][Full Text] [Related]
11. Cost-effective osteoporosis treatment thresholds: the United States perspective.
Tosteson AN; Melton LJ; Dawson-Hughes B; Baim S; Favus MJ; Khosla S; Lindsay RL;
Osteoporos Int; 2008 Apr; 19(4):437-47. PubMed ID: 18292976
[TBL] [Abstract][Full Text] [Related]
12. A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs.
Sander B; Elliot-Gibson V; Beaton DE; Bogoch ER; Maetzel A
J Bone Joint Surg Am; 2008 Jun; 90(6):1197-205. PubMed ID: 18519311
[TBL] [Abstract][Full Text] [Related]
13. The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden.
Willis MS
Int J Technol Assess Health Care; 2002; 18(4):791-807. PubMed ID: 12602080
[TBL] [Abstract][Full Text] [Related]
14. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial.
Majumdar SR; Lier DA; Beaupre LA; Hanley DA; Maksymowych WP; Juby AG; Bell NR; Morrish DW
Arch Intern Med; 2009 Jan; 169(1):25-31. PubMed ID: 19139320
[TBL] [Abstract][Full Text] [Related]
16. [Absolute risk for fracture and WHO guideline. Economic analysis of pharmacotherapy for osteoporosis].
Harada A;
Clin Calcium; 2007 Jul; 17(7):1029-34. PubMed ID: 17607069
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.
Borgström F; Johnell O; Jönsson B; Zethraeus N; Sen SS
Bone; 2004 Jun; 34(6):1064-71. PubMed ID: 15193554
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
Borgström F; Carlsson A; Sintonen H; Boonen S; Haentjens P; Burge R; Johnell O; Jönsson B; Kanis JA
Osteoporos Int; 2006; 17(7):996-1007. PubMed ID: 16570118
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.
Johnell O; Jönsson B; Jönsson L; Black D
Pharmacoeconomics; 2003; 21(5):305-14. PubMed ID: 12627984
[TBL] [Abstract][Full Text] [Related]
20. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
